Sophia Genetics, a Lausanne, Switzerland- and Boston, MA-based health tech company, closed a $77m funding round.
The round was led by Generation Investment Management, joined by Idinvest Partners, and existing investors including Balderton Capital and Alychlo.
The company, which has now raised a total of $140m, intends to use the funds to accelerate the reach of its data-driven medicine solutions add talent to reinforce its presence in the US.
Led by Dr. Jurgi Camblong, CEO and Founder, Sophia Genetics combines expertise in life sciences and medical disciplines with mathematical capabilities in data computing to provide a universal platform, called SOPHiA AI, that enables healthcare professionals to make sense of complex genomic and radiomic data through advanced analysis to diagnose and treat patients, both for oncology and hereditary disorders.
It is utilized by more than 850 hospitals across 77 countries and has already supported the diagnosis of over 300,000 patients.